Eli Lilly (NYSE:LLY) experienced a 6% increase in price over the last quarter, coinciding with several major developments.

The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...

We recently published a list of the 12 Stocks to Buy That May Be Splitting Soon. In this article, we are going to take a look ...

Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, bolstering the company’s argument that the siRNA candidate has an edge over ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/ ...

While you may be more familiar with brand names such as Ozempic or Wegovy, these drugs are known as glucagon-like peptide-1 ...

In a report released today, Geoff Meacham from Citi maintained a Buy rating on Eli Lilly & Co (LLY – Research Report). The company’s shares ...

Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...

The vote clears the way for a proposed multibillion-dollar expansion of the former Nexus Pharmaceuticals facility.